secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0001824293-25-000082
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRI Bio reports positive interim safety results from Phase 2a IPF study; IDMC recommends continuation
--------------------------------------------------------------------------------

- IDMC recommends study continue after no safety concerns in first 24 patients evaluated at 6 weeks.
- GRI-0621 safe and well-tolerated; no adverse events related to hyperlipidemia (LDL, HDL, TG).
- No clinically meaningful changes in HDL, LDL, or TG levels; all subjects within protocol ranges.
- Interim biomarker data expected July 2025; topline results from Phase 2a study expected Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429325000082/0001824293-25-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429325000082/val-20250626.htm
  HTML page:      https://secwatch.observer/filing/0001824293-25-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer